Trials / Completed
CompletedNCT00578175
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,851 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 14 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Priorix-Tetra™ (MMRV vaccine 208136) | One subcutaneous injection. |
| BIOLOGICAL | ProQuad® | One subcutaneous injection. |
| BIOLOGICAL | Havrix® | Two intramuscular injections. |
| BIOLOGICAL | Prevnar® | One intramuscular injection. |
Timeline
- Start date
- 2007-11-20
- Primary completion
- 2009-02-24
- Completion
- 2009-03-17
- First posted
- 2007-12-21
- Last updated
- 2018-10-09
- Results posted
- 2010-08-26
Locations
141 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00578175. Inclusion in this directory is not an endorsement.